1–10 mg — reported, not studied
1–10 mg once daily over 12 weeks, swallowed. The trials did not inject it, the 1 mg group lost 2.6 kg against 0.8 kg on placebo, the 10 mg group lost less than the 1 mg group, and the primary trial reports were never published.
| Water added | Concentration | Draw, low to high |
|---|---|---|
| 2 mL | 2.50 mg/mL | 40.0 to 400.0 unitswon’t fit |
| 3 mL | 1.67 mg/mL | 60.0 to 600.0 unitswon’t fit |
limited human dataValentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther 2010;87(6):652-62 — reports the AOD-9604 12-week trial arms (1 mg/day and 10 mg/day) and the 536-subject 24-week trial that ended development · retrieved 2026-08-12
